Cargando…

Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine

mRNA vaccines including Pfizer BioNTech and Moderna have categorically been considered safe when it comes to preventing COVID-19. However, there is still a small associated risk of thromboembolic phenomenon including venous sinus thrombosis with it and our case report highlights one. We describe a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Qureshi, Muhammad Imran Ahmad, Azam, Bilal, Waheed, Muhammad Aamir, Imran, Afsheen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125703/
https://www.ncbi.nlm.nih.gov/pubmed/35606039
http://dx.doi.org/10.1136/bcr-2021-247493
_version_ 1784711992974508032
author Qureshi, Muhammad Imran Ahmad
Azam, Bilal
Waheed, Muhammad Aamir
Imran, Afsheen
author_facet Qureshi, Muhammad Imran Ahmad
Azam, Bilal
Waheed, Muhammad Aamir
Imran, Afsheen
author_sort Qureshi, Muhammad Imran Ahmad
collection PubMed
description mRNA vaccines including Pfizer BioNTech and Moderna have categorically been considered safe when it comes to preventing COVID-19. However, there is still a small associated risk of thromboembolic phenomenon including venous sinus thrombosis with it and our case report highlights one. We describe a patient who developed severe progressive headache, tinnitus and visual disturbance symptoms post-Pfizer-SARS-CoV-2 vaccination. His medical history included essential tremors, hypertension, type 2 diabetes mellitus, chronic kidney disease stage 3, anxiety, depression and long-term catheterisation. Systemic examination revealed hypotonia, generalised reduced power and central diplopia along with peripheral visual field defect in the left eye. He was extensively investigated, the COVID-19 PCR test was negative and all routine blood tests were in the normal range except a marginally raised D-dimer of 779 ng/mL. CT head was unremarkable. He was also tested for myasthenia gravis; however, acetylcholine receptors antibodies were negative and nerve conduction studies were normal. Subsequent MRI of the brain with venography confirmed venous sinus thrombosis. A 24-hour Holter monitoring test did not reveal any cardiac rate or rhythm abnormality. He was treated with apixaban as per a neurologist’s advice. His clinical condition started to improve and was later discharged from the hospital with an outpatient neurologist clinic follow-up.
format Online
Article
Text
id pubmed-9125703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91257032022-06-04 Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine Qureshi, Muhammad Imran Ahmad Azam, Bilal Waheed, Muhammad Aamir Imran, Afsheen BMJ Case Rep Case Reports: Adverse drug reactions and complications mRNA vaccines including Pfizer BioNTech and Moderna have categorically been considered safe when it comes to preventing COVID-19. However, there is still a small associated risk of thromboembolic phenomenon including venous sinus thrombosis with it and our case report highlights one. We describe a patient who developed severe progressive headache, tinnitus and visual disturbance symptoms post-Pfizer-SARS-CoV-2 vaccination. His medical history included essential tremors, hypertension, type 2 diabetes mellitus, chronic kidney disease stage 3, anxiety, depression and long-term catheterisation. Systemic examination revealed hypotonia, generalised reduced power and central diplopia along with peripheral visual field defect in the left eye. He was extensively investigated, the COVID-19 PCR test was negative and all routine blood tests were in the normal range except a marginally raised D-dimer of 779 ng/mL. CT head was unremarkable. He was also tested for myasthenia gravis; however, acetylcholine receptors antibodies were negative and nerve conduction studies were normal. Subsequent MRI of the brain with venography confirmed venous sinus thrombosis. A 24-hour Holter monitoring test did not reveal any cardiac rate or rhythm abnormality. He was treated with apixaban as per a neurologist’s advice. His clinical condition started to improve and was later discharged from the hospital with an outpatient neurologist clinic follow-up. BMJ Publishing Group 2022-05-19 /pmc/articles/PMC9125703/ /pubmed/35606039 http://dx.doi.org/10.1136/bcr-2021-247493 Text en © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.
spellingShingle Case Reports: Adverse drug reactions and complications
Qureshi, Muhammad Imran Ahmad
Azam, Bilal
Waheed, Muhammad Aamir
Imran, Afsheen
Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
title Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
title_full Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
title_fullStr Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
title_full_unstemmed Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
title_short Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
title_sort venous sinus thrombosis after the first dose of pfizer biontech vaccine
topic Case Reports: Adverse drug reactions and complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125703/
https://www.ncbi.nlm.nih.gov/pubmed/35606039
http://dx.doi.org/10.1136/bcr-2021-247493
work_keys_str_mv AT qureshimuhammadimranahmad venoussinusthrombosisafterthefirstdoseofpfizerbiontechvaccine
AT azambilal venoussinusthrombosisafterthefirstdoseofpfizerbiontechvaccine
AT waheedmuhammadaamir venoussinusthrombosisafterthefirstdoseofpfizerbiontechvaccine
AT imranafsheen venoussinusthrombosisafterthefirstdoseofpfizerbiontechvaccine